益佰制药(600594.SH)：前三季度净亏损8656.26万元

Core Viewpoint - Yibai Pharmaceutical (600594.SH) reported a decline in revenue and a net loss for the first three quarters of 2025, indicating ongoing financial challenges [1] Financial Performance - The company achieved total operating revenue of 1.447 billion yuan for the first three quarters, representing a year-on-year decrease of 15.59% [1] - The net profit attributable to shareholders of the parent company was -86.5626 million yuan, which is an improvement of 82.5887 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.11 yuan [1]